ZA200510458B - N-{4-substituted piperazine-1-sulfonylmethylalkyl}-N-hydroxyfomamide compounds are metalloproteinase inhibitors - Google Patents

N-{4-substituted piperazine-1-sulfonylmethylalkyl}-N-hydroxyfomamide compounds are metalloproteinase inhibitors

Info

Publication number
ZA200510458B
ZA200510458B ZA200510458A ZA200510458A ZA200510458B ZA 200510458 B ZA200510458 B ZA 200510458B ZA 200510458 A ZA200510458 A ZA 200510458A ZA 200510458 A ZA200510458 A ZA 200510458A ZA 200510458 B ZA200510458 B ZA 200510458B
Authority
ZA
South Africa
Prior art keywords
sulfonylmethylalkyl
hydroxyfomamide
compounds
metalloproteinase inhibitors
substituted piperazine
Prior art date
Application number
ZA200510458A
Other languages
English (en)
Inventor
Finlay Maurice Raymond Verschoyle
Waterson David
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27656653&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200510458(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA200510458B publication Critical patent/ZA200510458B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200510458A 2003-06-27 2005-12-22 N-{4-substituted piperazine-1-sulfonylmethylalkyl}-N-hydroxyfomamide compounds are metalloproteinase inhibitors ZA200510458B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0301922A SE0301922D0 (sv) 2003-06-27 2003-06-27 Novel compounds

Publications (1)

Publication Number Publication Date
ZA200510458B true ZA200510458B (en) 2007-03-28

Family

ID=27656653

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200510458A ZA200510458B (en) 2003-06-27 2005-12-22 N-{4-substituted piperazine-1-sulfonylmethylalkyl}-N-hydroxyfomamide compounds are metalloproteinase inhibitors

Country Status (34)

Country Link
US (1) US7485644B2 (ar)
EP (1) EP1644340B1 (ar)
JP (1) JP4701167B2 (ar)
KR (1) KR20060026440A (ar)
CN (2) CN1812974B (ar)
AR (1) AR044931A1 (ar)
AT (1) ATE414063T1 (ar)
AU (1) AU2004251104B2 (ar)
BR (1) BRPI0411929A (ar)
CA (1) CA2529468A1 (ar)
CO (1) CO5650254A2 (ar)
CY (1) CY1108757T1 (ar)
DE (1) DE602004017733D1 (ar)
DK (1) DK1644340T3 (ar)
ES (1) ES2315675T3 (ar)
HK (1) HK1086835A1 (ar)
HR (1) HRP20090009T3 (ar)
IL (1) IL172615A0 (ar)
IS (1) IS8257A (ar)
MX (1) MXPA05013460A (ar)
MY (1) MY138680A (ar)
NO (1) NO20060444L (ar)
NZ (1) NZ544208A (ar)
PL (1) PL1644340T3 (ar)
PT (1) PT1644340E (ar)
RU (1) RU2351595C2 (ar)
SA (1) SA04250224B1 (ar)
SE (1) SE0301922D0 (ar)
SI (1) SI1644340T1 (ar)
TW (1) TW200524898A (ar)
UA (1) UA81491C2 (ar)
UY (1) UY28387A1 (ar)
WO (1) WO2005000822A1 (ar)
ZA (1) ZA200510458B (ar)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0427403D0 (en) 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
EA013907B1 (ru) * 2005-10-26 2010-08-30 Мерк Сероно С.А. Сульфонамидные производные и их применение для модулирования металлопротеаз
CN101007794B (zh) * 2006-01-26 2010-09-01 中国科学院上海药物研究所 N,n'-二取代哌嗪类衍生物及其制备方法、药物组合物和用途
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
HUE030114T2 (en) * 2010-07-08 2017-04-28 Kaken Pharma Co Ltd N-hydroxyformamide derivatives and pharmaceutical compositions containing them

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2317455C (en) 1998-01-30 2011-01-25 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
US6916817B1 (en) * 1999-06-04 2005-07-12 Astrazeneca Ab Inhibitors of metalloproteinases
RU2283306C2 (ru) * 2000-02-21 2006-09-10 Астразенека Аб Пиперидин- и пиперазинзамещенные n-гидроксиформамиды в качестве ингибиторов металлопротеиназ
GB0119472D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
AU2003221786A1 (en) * 2002-04-25 2003-11-10 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
ATE411303T1 (de) * 2003-06-19 2008-10-15 Ucb Pharma Sa Hydroxamatsulfonamide als inhibitoren von cd23- shedding

Also Published As

Publication number Publication date
EP1644340B1 (en) 2008-11-12
NZ544208A (en) 2009-02-28
SA04250224B1 (ar) 2009-05-31
MY138680A (en) 2009-07-31
AU2004251104B2 (en) 2008-05-08
BRPI0411929A (pt) 2006-08-15
IS8257A (is) 2006-01-23
RU2351595C2 (ru) 2009-04-10
RU2005141058A (ru) 2006-07-27
NO20060444L (no) 2006-03-22
MXPA05013460A (es) 2006-03-09
CO5650254A2 (es) 2006-06-30
EP1644340A1 (en) 2006-04-12
UA81491C2 (en) 2008-01-10
KR20060026440A (ko) 2006-03-23
CN1812974B (zh) 2011-06-29
ES2315675T3 (es) 2009-04-01
DK1644340T3 (da) 2009-02-02
HK1086835A1 (en) 2006-09-29
HRP20090009T3 (en) 2009-02-28
CN102229589A (zh) 2011-11-02
CN1812974A (zh) 2006-08-02
SI1644340T1 (sl) 2009-02-28
WO2005000822A1 (en) 2005-01-06
DE602004017733D1 (de) 2008-12-24
US20070197542A1 (en) 2007-08-23
SE0301922D0 (sv) 2003-06-27
AU2004251104A1 (en) 2005-01-06
TW200524898A (en) 2005-08-01
JP4701167B2 (ja) 2011-06-15
AR044931A1 (es) 2005-10-12
PL1644340T3 (pl) 2009-04-30
CA2529468A1 (en) 2005-01-06
ATE414063T1 (de) 2008-11-15
UY28387A1 (es) 2005-01-31
PT1644340E (pt) 2009-01-02
US7485644B2 (en) 2009-02-03
JP2007516164A (ja) 2007-06-21
IL172615A0 (en) 2006-04-10
CY1108757T1 (el) 2014-04-09

Similar Documents

Publication Publication Date Title
IS7505A (is) Pýrróló-tríazín anilín efnasambönd gagnleg sem kínasatálmar
GB2404536B (en) Protection of data
DE60320933D1 (de) Rho-kinase inhibitoren
IL209082A0 (en) Fushed heterocyclic compounds
DK1534290T3 (da) Hidtil ukendte kinasehæmmere
DE602004018837D1 (de) Ptidase-iv-inhibitoren
IS7599A (is) Heterósýklískir kínasatálmar
IL157652A0 (en) Metalloproteinase inhibitors
IL157570A0 (en) Metalloproteinase inhibitors
EP1551801A4 (en) NOVEL GAMMA-LACTAMES AS INHIBITORS OF BETA-SECRETASE
HK1077762A1 (zh) TFGß[轉化生長因子]的抑制劑
ZA200705075B (en) Novel hydantoin derivatives as metalloproteinase inhibitors
IL157650A0 (en) Metalloproteinase inhibitors
IL183667A0 (en) Novel hydantoin derivatives as metalloproteinase inhibitors
IS7833A (is) Efnasambönd með sameinaða heteróhringi
PL378116A1 (pl) Heterocykliczne inhibitory kinazy
IL165475A0 (en) Nitrooxyderivatives of eyclooxygenase-2 inhibitors
EP1663279A4 (en) MODIFIED PROTEASE INHIBITORS
ZA200510458B (en) N-{4-substituted piperazine-1-sulfonylmethylalkyl}-N-hydroxyfomamide compounds are metalloproteinase inhibitors
DK1667975T3 (da) En polymorf form for 3-phenylsulfonyl-8-piperazin-1-yl-quinolin
NO20034109L (no) Parafininhibitor-komposisjon
EP1531857A4 (en) Metalloproteinase inhibitors
IS7963A (is) Efnasambönd með hamlandi virkni gegn prólýlólígópeptíðasa
DE60316425D1 (de) NF-kappaB-INHIBITOREN
PL375304A1 (en) N-sulfonylpiperidines as metalloproteinase inhibitors (tace)